Abstracts
  1. Barnes MP. Medicinal cannabis. 10th World Congress of Neurological Rehabilitation, Mumbai, January 2018

  2. Barnes MP. Medicinal cannabis. Asia-Oceania Congress on Neurological Rehabilitation, Tagaytay City, Philippines, August 2017

  3. Barnes MP. Medicinal cannabis. 11th World Congress of International Society of Physical and Rehabilitation Medicine, Buenos Aires Argentina, May 2017

  4. Barnes MP. Medicinal cannabis. Chinese Congress on Neurological Rehabilitation, Shanghai China,  March 2017

  5. Barnes M, Kocer S, Fernandez MM, Balcaitiene J, Fheodoroff K.  How do people with spasticity view their care?  Findings from an international patient survey.  20th European Congress of Physical and Rehabilitation Medicine.  Lisbon Portugal, April 2016 

  6. Kanovsky P, Barnes M.  Botulinum neurotoxin in upper limb spasticity.  45th International Danube Neurology Symposium 2013.  Prague Czech Republic, November 2013

  7. van Wijck F, Shaw L, Price C, Shackley P, Steen N, Barnes M, Ford G, Graham L, Rodgers H on behalf of the BoTULS investigators.  Botulinum toxin for the upper limb after stroke (BOTULS) trial: effect on patient-selected goals versus a standard arm function test.  8th World Stroke Congress, Brasilia Brazil, October 2012 (oral presentation)

  8. Kanovsky P, Barnes M, Pulte I, Grafe S.  Significant and sustained efficacy of incobotulinumtoxinA (Xeomin®;  botulinum neurotoxin type A, free from accessory proteins) in upper limb spasticity.  American Acdemy of Physical Medicine and Rehabilitation, Orlando USA, November 2011

  9. Butler AG, Duffey POF, Hawthorne MR, Barnes MP.  The epidemiological survey of dystonia (ESD) within the population of North East England over the past eighteen and a half years.  5th International Dystonia Symposium, Barcelona Spain, October 2011

  10. Kanovsky P, Barnes M, Pulte I, Grafe S.  Significant and sustained efficacy of incobotulinumtoxinA (Xeomin®;  botulinum neurotoxin type A, free from accessory proteins) in upper limb spasticity.  Toxins 2011 – 7th International Conference on Basic and Therapeutic Aspects of Botulinum and Tetnaus Toxins.  Santa Fe, New Mexico, USA, October 2011

  11. Barnes M, Schnitzler A, Amaral e Silva A, et al.  Different dilutions of NT201 (Xeomin®;  Botulinum neurotoxin free from complexing proteins) is efficacious and well-tolerated in upper limb spasticity of various etiologies.  American Academy of Physical Medicine and Rehabilitation, Seattle USA, November 2010 

  12. Kanovsky P, Barnes M, Pulte I, Minnasch P, Grafe S, for the NT 201 Spasticity Study Group.  Efficacy of NT 201 (Botulinum neurotoxin type A, free from complexing proteins) in the treatment of patients with upper limb spasticity.  14th International Congress of Parkinson’s Disease and Movement Disorders.  Buenos Aires Argentina, June 2010 

  13. Shaw LC, van Wijck FMJ, Price, CIM et al.  Analysis of patient selected goals from the Botulinum Toxin for the Upper Limb after Stroke (BoTULS) trial.  European Stroke Conference. Barcelona Spain, May 2010

  14. Barnes M, Schnitzler A, Amaral e Silva A, et al.  Different dilutions of NT201 (Xeomin®;  Botulinum neurotoxin free from complexing proteins) is efficacious and well-tolerated in upper limb spasticity of various etiologies.  European Stroke Conference. Barcelona Spain, May 2010 

  15. Kanovsky P, Barnes M, Pulte I, Minnasch P, Grafe S, for the NT 201 Spasticity Study Group.  Efficacy of NT 201 (Botulinum neurotoxin type A, free from complexing proteins) in the treatment of patients with upper limb spasticity.  European Stroke Conference. Barcelona Spain, May 2010 

  16. Kanovsky P, Barnes M, Pulte I, Minnasch P, Grafe S, for the NT 201 Spasticity Study Group.  Efficacy of NT 201 (Botulinum neurotoxin type A, free from complexing proteins) in the treatment of patients with upper limb spasticity.  62nd Annual Meeting of the American Academy of Neurology.  Toronto Canada, April 2010 

  17. Omran B, Barnes MP, Graham L, Johnson GR.  A novel test to measure upper limb motor function - instrumented peg-in-hole technique.  6th World Congress for NeuroRehabilitation, Vienna Austria, March 2010

  18. Barnes M, Schnitzler A, Amaral e Silva A, et al.  Different dilutions of NT201 (Xeomin®;  Botulinum neurotoxin free from complexing proteins) is efficacious and well-tolerated in upper limb spasticity of various etiologies. 19th World Congress of Neurology, Bangkok Thailand, October 2009

  19. Barnes M, Schnitzler A, Amaral A, et al.  NT201 (Xeomin® - Botulinum neurotoxin free from complexing proteins) is efficacious and well-tolerated in upper limb spasticity of various aetiologies: Results from a prospective, randomized, parallel group trial.  5th World Congress of the ISPRM, Istanbul Turkey, June 2009 

  20. Barnes M, Schnitzler A, Amaral A, et al.  NT201(Xeomin® - Botulinum neurotoxin free from complexing proteins) is efficacious and well-tolerated in upper limb spasticity of various aetiologies: Results from a prospective, randomized, parallel group trial.  MDS 13th International Congress, Paris France, June 2009 

  21. Shaw L, Price C, van Wijck F, Barnes M et al.  BoTULS: A multi-centre randomised controlled trial to evaluate the clinical effect of treating upper limb spasticity due to stroke with botulinum toxin type A.  XVIII European Stroke Conference, Stockholm Sweden, May 2009

  22. Shaw L, Price C, van Wijck F, Barnes M et al.  A randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin: one month results.  The Society for Research in Rehabilitation Winter 2009 Meeting, Derby UK, February 2009 

  23. Shaw L, Price C, van Wijck F, Barnes M et al.  A randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin.  World Stroke Congress, Vienna Austria, September 2008 

  24. Shaw L, Price CIM, van Wijck F, Barnes M et al.  A randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin.  Stroke Research Network Annual Conference, Newcastle upon Tyne UK, June 2008

  25. Barnes MP.  Global impact and management of spasticity and the role of organised neurorehabilitation in its management.  Neurorehabil Neural Repair 2008; 22(2): 198

  26. Barnes MP.  Neurorehabilitation in the 21st century.  Neurorehabil Neural Repair 2008; 22(2): 194

  27. Botulinum toxin type-A combined with task-specific practice in people with chronic upper limb spasticity after stroke – a feasibility RCT.  UK Stroke Forum Conference, Harrogate UK, December 2006

  28. KA Foster, F van Wijck, CIM Price, et al.  What is the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin?  British Association of Stroke Physicians, Bournemouth UK, February 2006

  29. van Wijck F, Price CIM, Barnes MP, Ford GA, Rodgers H.  What is the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin?  4th World Congress for NeuroRehabilitation, Hong Kong, February 2006

  30. van Wijck F, Mackenzie J, Pandyan AD, Barnes MP, Johnson G.  Improving functional activity of the spastic upper limb in the chronic stage after stroke following botulinum toxin.  4th World Congress for NeuroRehabilitation, Hong Kong, February 2006

  31. Foster KA, van Wijck F, Price C, Graham LA, Gani A, Barnes M et al.  What is the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin?  Northern Regional meeting of the British Geriatrics Society, North Shields UK, September 2005

  32. Barnes M, Collin C, Stott C.  Are changes in self reported levels of spasticity on a 0-10 Numerical Rating Scale clinically important?  21st Congress of the European Committee/10th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis, Thessaloniki Greece, September/October 2005

  33. van Wijck F, Mackenzie J, Hooper J, Pandyan AD, Barnes M, Johnson G (2005). Skill acquisition in stroke patients with chronic upper limb spasticity: combining botulinum toxin with task-orientated motor learning.     Proceedings of the South African Society of Physiotherapy 2nd International Congress, Johannesburg South Africa, 23-29 May 2005

  34. Salazar-Torres J, Pandyan AD, Price C, Barnes M, Johnson G.  Velocity dependency of the stretch reflex response in post-stroke spasticity.  Spasticity: Evidence Based Measurement and Treatment.  Newcastle upon Tyne UK, 9-11 December 2004

  35. Salazar-Torres J, Pandyan AD, Price C, Barnes M, Johnson GR.  Influence of head position in the stretch reflex excitability in post-stroke and non-impaired volunteers.  Spasticity: Evidence Based Measurement and Treatment.  Newcastle upon Tyne UK, 9-11 December 2004

  36. Pandyan AD, van Wijck FMJ, Stark S, Vuadens P, Johnson GR, Barnes MP.  Measuring aspects of spasticity: a simple clinical approach to routine measurement.  Spasticity: Evidence Based Measurement and Treatment.  Newcastle upon Tyne UK, 9-11 December 2004

  37. van Wijck F, Mackenzie J, Hooper J, Pandyan AD, Barnes M, Johnson G.  Effects of botulinum toxin and motor learning on upper limb function in stroke patients with chronic spasticity: standardised versus patient-centred outcomes.  Spasticity: Evidence Based Measurement and Treatment.  Newcastle upon Tyne UK, 9-11 December 2004

  38. van Wijck F, Mackenzie J, Hooper J, Barnes MP, Johnson GR.  Improving arm function in patients with chronic spasticity: combining botulinum toxin with a task-orientated motor learning programme.  Int J Rehab Res 2004; 27 (Suppl 1): 109

  39. Roberts B, Whitaker J, Barnes MP.  Antibodies to botulinum toxin and associated proteins as found in the normal human population.  DSTL symposium, Oxford UK, October 2003

  40. Salazar-Torres J de J, Pandyan AD, Price CIM, Davidson RI, Barnes MP, Johnson GR.  Biomechanical characterisation of the stretch reflex activity as an approach to spasticity measurement and modelling – a pilot study.  25th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Cancun Mexico, September 2003.

  41. Salazar-Torres J, Pandyan A, Price C, Barnes M, Johnson GR.  Does spasticity result from hyperactive stretch reflexes?  Preliminary findings from a reflex characterisation study.  2nd World Congress of the International Society of Physical and Rehabilitation Medicine. Prague, Czech Republic,  May 2003

  42. Salazar-Torres J de J, Pandyan AD, Price CIM, Barnes MP, Johnson GR.  Effects of initial muscle length in stretch reflex excitability in people with post-stroke spasticity and healthy volunteers. 27th Annual meeting of the American Society of Biomechanics, Ohio USA, September 2003

  43. Salazar-Torres J, Pandyan, A, Price C, Barnes M, Johnson GR.  Variations in the stretch reflex excitability due to applied torque perturbations in post-stroke and non-impaired volunteers.  World Congress of Medical Physics & Biomedical Engineering (Triennial Congress of the IUPESM/IFMBE/IOMP). Sydney Australia, August 2003

  44. Roberts B, Whitaker J, Barnes MP.  Measurement of antibodies to clostridium botulinum types A-F, in the complexed and uncomplexed forms, in dystonia patients showing secondary resistance to therapy.  Naunyn-Schmiedeberg’s Arch Pharmacol 2002; 365(Suppl 2): 110

  45. Stark S, Tindall CE, Atkin HM, van Wijck FMJ, Alexander S, Barnes MP, Pandyan A.  A retrospective study of upper limb problems and their associated interventions following neurological event.  3rd World Congress of Neurological Rehabilitation. Venice Italy, April 2002 

  46. Graham LA, Barnes MP.  Morbidity and fatigue induced by head up tilt as a physiotherapy intervention in patients with brain injury: a pilot study.  3rd World Congress of Neurological Rehabilitation, Venice 2002

  47. Salazar-Torres J de J, Pandyan AD, Price CIM, Davidson RI, Barnes MP, Johnson GR.  Biomechanical characterisation of reflex activity at the elbow – a first step to quantifying spasticity.  3rd World Congress of Neurological Rehabilitation. Venice Italy, April 2002

  48. Pandyan AD, Vuadens P, van Wijck, Stark S, Johnson GR, Barnes MP.  A simple biomechanically based technique to measure spasticity in routine clinical practice – results from a preliminary clinical trial.  3rd World Congress of Neurological Rehabilitation. Venice Italy, April 2002 

  49. Pandyan AD, Price CIM, Barnes MP, Johnson GR.  A simple biomechanical technique for the clinical quantification of resistance to passive movement in rehabilitation.  International Society of Biomechanics XVIII Congress. Zurich Switzerland, July 2001

  50. Pandyan AD, Vuadens P, van Wijck FMJ, Stark S, Johnson GR, Barnes MP.  Outcome measures for treatment with botulinum toxin type A (Botox) for elbow spasticity in a chronic post-stroke population.  Proceedings of 1st World Congress of the International Society of Physical and Rehabilitation Medicine.  Amsterdam 2001

  51. Pandyan AD, Vuadens P, van Wijck FMJ, Stark S, Johnson GR, Barnes MP.  Is the clinical efficacy of botulinum toxin type-A (Botox®) being underestimated in post stroke hemiplegia?  Proceedings of 1st World Congress of the International Society of Physical and Rehabilitation Medicine.  Monduzzi Editore Italy 2001, p152

  52. Pandyan AD, Price CIM, Rodgers H, Barnes MP, Johnson GR.  A quantitative investigation into the construct validity of the modified Ashworth scale.  Proceedings of 1st World Congress of the International Society of Physical and Rehabilitation Medicine. Monduzzi Editore Italy 2001, p142

  53. Barnes M.  Hemiplegic shoulder pain: central causes and treatment.  Proceedings of 1st World Congress of the International Society of Physical and Rehabilitation Medicine. Monduzzi Editore Italy 2001, p151

  54. Barnes M.  Rehabilitation in the community: opportunities and threats.  Proceedings of 1st World Congress of the International Society of Physical and Rehabilitation Medicine. Monduzzi Editore Italy 2001, p89

  55. Pandyan AD, Vuadens P, van Wijck FMJ, Stark S, Johnson GR, Barnes MP.  Clinical efficacy of botulinum toxin type A (Botox®) in a chronic stroke population: paradoxical findings from objective measures of spasticity and strength.  Journal of the Neurological Sciences 2001; 187(S1): S217 

  56. van Wijck FMJ, Pandyan AD, Johnson GR, Barnes MP.  Assessing motor deficits in neurological rehabilitation: a profile of instrument usage.  Journal of the Neurological Sciences 2001; 187(S1): S184

  57. Pandyan AD, Price CIM, Rodgers H, Barnes MP, Johnson GR.  A catch in the modified Ashworth Scale: is there a biomechanical correlate?  Journal of the Neurological Sciences 2001; 187(S1): S183 

  58. Pandyan AD, Price CIM, Rodgers H, Barnes MP, Johnson GR.  A clinical tool to measure resistance to passive movement: a biomechanical alternative to the clinical grading of spasticity.  Proceedings of Society for Research in Rehabilitation Liverpool, 2000

  59. Barnes MP.  Extended ADL scales and quality of life measures in stroke.  Eur J Neurol 2000; 7(Suppl 3): 146

  60. Cullis PA, Barnes MP, Duane D et al.  Safety and tolerability of repeat doses of NeuroBlocTM (botulinum toxin Type B) in patients with cervical dystonia: an open label, dose escalation study.  Movement Disorders 2000; 15(Suppl 2) p29-30

  61. Pandyan AD, Price CIM, Barnes MP, Johnson GR.  Assessing resistance to passive movement: Are repeated measures necessary?  Eur J Neurol 1999; 6(Suppl3): 66 

  62. Kent RM, Barnes MP.  Transport needs of disabled people living in a rural environment. Neurorehabilitation & Neural Repair 1999; 13(1): 71

  63. Kent RM, Chandler BJ, Barnes MP.  Service provision for disabled people living in a rural environment. Neurorehabilitation & Neural Repair 1999; 13(1): 72

  64. Barnes MP, Whitaker J.  Botulinum toxin treatment for people with dystonia treated by an outreach nurse practitioner. Neurorehabilitation & Neural Repair 1999; 13(1): 74

  65. Semlyen JK, Kent RM, Barnes MP.  The impact of spasticity on disability in MS.  Neurorehabilitation & Neural Repair 1999; 13(1): 75

  66. Pandyan AD, Price CIM, Curless R, Barnes MP, Johnson GR.  A simple technique to quantify resistance to passive movement: a first step towards developing an objective clinical measure of spasticity. Neurorehabilitation & Neural Repair 1999; 13(1): 58

  67. Pandyan AD, Price CIM, Curless R, Barnes MP, Johnson GR.  The Ashworth scales: are they valid and reliable measures of spasticity? Neurorehabilitation & Neural Repair 1999; 13(1): 58

  68. Semlyen JK, Summers SJ, Barnes MP.  The Newcastle Independence Assessment Form: precision and prediction. Neurorehabilitation & Neural Repair 1999; 13(1): 24

  69. Semlyen, JK, Barnes MP, Makepeace, R.  Effectiveness of a community multiple sclerosis team. Neurorehabilitation & Neural Repair 1999; 13(1): 75

  70. Pandyan AD, Price C, Rodgers H, Curless R, Barnes MP, Johnson GR.  Can quantifying resistance to passive movement provide a valid measure of spasticity?  Proceedings of Bioengineering in the North East, University of Durham, 1998

  71. Duffey P, Butler AG, Barnes MP.  The epidemiology of dopa-responsive dystonia in the North of England.  Eur J Neurol 1997; 4(Suppl 1): S67

  72. Barnes MP.  Experience of botulinum toxin in the management of spasticity.  Eur J Neurol 1997; 4(2): S33-36

  73. Johnson GR, Barnes MP.  Experience of a MSc course in Rehabilitation Management.  Eur J Neurol 1996; 3(Suppl 2): 22-23

  74. Wright D, Barnes MP, Daymond TJ.  Assessment of the risk of osteoporosis in postmenopausal women with poor mobility.  Eur J Neurol 1996; 3(Suppl 2): 19

  75. Field A, Barnes MP.  Botulinum toxin in dystonia treatment.  A 12 month retrospective review.  Eur J Neurol 1996; 3(Suppl 2): 78-79

  76. Field A, Barnes MP.  Current usage of botulinum toxin in spasticity - clinical and financial considerations. Eur J Neurol 1996; 3(Suppl 2): 23

  77. Kent R, Chandler BJ, Barnes MP.  Less than their fair share?  An exploration of inequity in community care between the young disabled and the elderly in a rural community.  Eur J Neurol 1996; 3(Suppl 2): 31

  78. Barnes MP.  The management of spasticity. Eur J Neurol 1996; 3(Suppl 2): 3 

  79. barnes MP.  UK national dystonia database. Movement Disorders 1995; 10: 391

  80. Barnes MP, Field AB.  The knowledge of dystonia and the use of botulinum toxin amongst primary care physicians in the United Kingdom.  Movement Disorders 1995; 10: 391 

  81. Castree BJ, Barnes MP.   Community care: A paper definition or a practical reality?  Clin Rehab 1993; 7: 84  

  82. Castree BJ, Barnes MP.  Informal care networks - One of the keys to community care.  Clin Rehab 1992; 6(Suppl): 40-41 

  83. Hoyle  EA, Castree BJ, Barnes MP.  Newcastle  upon Tyne Community Disability Study.  Clin Rehab 1991; 5: 40  

  84. Castree  BJ, Barnes MP.  Young disabled people in institutional care.  Clin Rehab 1991; 5: 171  

  85. Barnes MP, Saunders M.  Cervical mobility and cervical spondylotic myelopathy.  Can J Neuro Sci 1983; 10: 130 

© 2019 by Mike Barnes

  • Twitter Clean Grey
  • LinkedIn Clean Grey